| Autor: |
Kroon, Cornelis D de, Jonge, Marthe M de, Bosse, Tjalling, Asperen, Christi J van, de Kroon, Cornelis D, de Jonge, Marthe M, van Asperen, Christi J |
| Předmět: |
|
| Zdroj: |
JNCI: Journal of the National Cancer Institute; Feb2022, Vol. 114 Issue 2, p322-323, 2p |
| Abstrakt: |
It is well known that patients with EC after at least 5 years tamoxifen use are at increased EC mortality risk compared with never users (hazard ratio = 1.59, 95% confidence interval = 1.13 to 2.25) ([3]). In our opinion, we should start today to consider EC and especially p53-abnormal EC and serous-like EC part of the hereditary breast and ovarian cancer syndrome caused by I gBRCA1/2 i mutations. But most of all, we are pleased with their support of our statement that, given the increased risks of I gBRCA1/2 i mutation carriers to develop p53-abnormal (11- to 12-fold) and serous-like endometrial cancer (8- to 10-fold) presented in our article, endometrial cancer (EC) and especially p53-abnormal and serous-like EC should be considered part of the hereditary breast and ovarian cancer syndrome caused by a I gBRCA1/2 i mutation. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
